BioVersys AG Statistics
Total Valuation
BioVersys AG has a market cap or net worth of CHF 166.67 million. The enterprise value is 105.89 million.
| Market Cap | 166.67M |
| Enterprise Value | 105.89M |
Important Dates
The last earnings date was Wednesday, March 18, 2026.
| Earnings Date | Mar 18, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
BioVersys AG has 5.85 million shares outstanding. The number of shares has increased by 68.49% in one year.
| Current Share Class | 5.85M |
| Shares Outstanding | 5.85M |
| Shares Change (YoY) | +68.49% |
| Shares Change (QoQ) | +8.71% |
| Owned by Insiders (%) | 3.13% |
| Owned by Institutions (%) | 10.09% |
| Float | 4.29M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 52.49 |
| PB Ratio | 2.79 |
| P/TBV Ratio | 2.79 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -4.85 |
| EV / Sales | 33.35 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -4.78 |
Financial Position
The company has a current ratio of 10.10, with a Debt / Equity ratio of 0.36.
| Current Ratio | 10.10 |
| Quick Ratio | 9.55 |
| Debt / Equity | 0.36 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.98 |
| Interest Coverage | -18.54 |
Financial Efficiency
Return on equity (ROE) is -61.94% and return on invested capital (ROIC) is -22.85%.
| Return on Equity (ROE) | -61.94% |
| Return on Assets (ROA) | -19.87% |
| Return on Invested Capital (ROIC) | -22.85% |
| Return on Capital Employed (ROCE) | -24.42% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | 96,212 |
| Profits Per Employee | -661,515 |
| Employee Count | 33 |
| Asset Turnover | 0.05 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, BioVersys AG has paid 16,000 in taxes.
| Income Tax | 16,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -17.98% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -17.98% |
| 50-Day Moving Average | 25.32 |
| 200-Day Moving Average | 27.29 |
| Relative Strength Index (RSI) | 60.37 |
| Average Volume (20 Days) | 4,559 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, BioVersys AG had revenue of CHF 3.18 million and -21.83 million in losses. Loss per share was -3.89.
| Revenue | 3.18M |
| Gross Profit | 3.18M |
| Operating Income | -19.96M |
| Pretax Income | -21.81M |
| Net Income | -21.83M |
| EBITDA | -19.89M |
| EBIT | -19.96M |
| Loss Per Share | -3.89 |
Balance Sheet
The company has 82.51 million in cash and 21.73 million in debt, with a net cash position of 60.78 million or 10.39 per share.
| Cash & Cash Equivalents | 82.51M |
| Total Debt | 21.73M |
| Net Cash | 60.78M |
| Net Cash Per Share | 10.39 |
| Equity (Book Value) | 59.81M |
| Book Value Per Share | 10.23 |
| Working Capital | 80.98M |
Cash Flow
In the last 12 months, operating cash flow was -21.95 million and capital expenditures -216,000, giving a free cash flow of -22.16 million.
| Operating Cash Flow | -21.95M |
| Capital Expenditures | -216,000 |
| Depreciation & Amortization | 70,000 |
| Net Borrowing | 2.67M |
| Free Cash Flow | -22.16M |
| FCF Per Share | -3.79 |
Margins
| Gross Margin | 100.00% |
| Operating Margin | -628.76% |
| Pretax Margin | -687.06% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
BioVersys AG does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -68.49% |
| Shareholder Yield | -68.49% |
| Earnings Yield | -13.10% |
| FCF Yield | -13.30% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
BioVersys AG has an Altman Z-Score of 2.34 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.34 |
| Piotroski F-Score | 1 |